# Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice Canonical URL: https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-announces-resolution-of-nasdaq-deficiency-notice Ticker: PTIX Company: Protagenic Therapeutics Source: Protagenic Therapeutics Published: 2024-03-21 08:41 EST Original Source URL: https://www.pressviewer.com ## Summary

NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, regained compliance with Nasdaq Listing Rule 5550(a)(2) as the closing bid price of shares of PTIX has remained above $1.00 per share for ten conse ## Article Body NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, regained compliance with Nasdaq Listing Rule 5550(a)(2) as the closing bid price of shares of PTIX has remained above $1.00 per share for ten consecutive trading days. This resolves the issue of potential delisting from Nasdaq by May 19, 2024 that the company had been facing. On Tuesday, November 21, 2023, the company... ## Recent Company News - 2026-05-19 08:15 EST — [Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-engages-floyd-regulatory-strategic-consulting-as-regulatory-affairs-advisor-and-danforth-health-as-strategic-operations-partner) — Source: Protagenic Therapeutics - 2026-04-23 08:15 EST — [Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-appoints-industry-veteran-bill-nichols-jr-as-president-to-accelerate-advancement-of-first-in-class-tcap-pathway-therapy-pt00114) — Source: Protagenic Therapeutics - 2026-03-17 08:00 EST — [Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-completes-phytanix-separation-strengthens-balance-sheet-and-repositions-the-company-around-pt00114) — Source: Protagenic Therapeutics - 2026-03-10 08:00 EST — [Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-upgrades-from-otc-pink-to-otcqb-venture-market) — Source: Protagenic Therapeutics - 2025-12-09 08:46 EST — [Results from Phase 1 Multiple-Dose Study of PT00114](https://biopharmsignal.com/news/PTIX/results-from-phase-1-multiple-dose-study-of-pt00114) — Source: Protagenic Therapeutics ## Related News - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec) - 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)